2017-11-14T12:38:37-06:00 2016-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 650N BETHESDA MD 208142930 990 2016-01-01 943384500 PATH DRUG SOLUTIONS PATH 2062853500 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 OLIVIA D POLIUS CHIEF FINANCIAL OFFICER 2062853500 2017-11-14 1 3019519090 75.103.231.202 2017-11-14 13:38:12 ES P 24E2B1EDDFB7997E904F8C8AA54720A5F314F67A 1C84E1F40D0AB4F75A6C29AABE8087358D4F1C89 2016 2017-02-10 21:41:12Z OLIVIA D POLIUS 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 216478 0 X WWW.PATH.ORG X 2000 CA SEE PART III, LINE 1. 8 3 0 0 0 0 7126779 163077 0 0 12936 50401 0 3000 7139715 216478 4768944 2597185 0 0 0 0 0 0 0 1228767 678532 5997711 3275717 1142004 -3059239 14847024 10229897 1605303 46385 13241721 10183512 X PATH DRUG SOLUTIONS (PDS) DEVELOPS AND ADVANCES SAFE AND EFFECTIVE MEDICINES FOR THE PREVENTION AND TREATMENT OF DISEASES DISPROPORTIONATELY AFFECTING WOMEN AND CHILDREN IN LOW-RESOURCE SETTINGS. WE WORK WITH A VARIETY OF PUBLIC- AND PRIVATE-SECTOR STAKEHOLDERS TO BUILD CROSS-SECTOR COLLABORATIONS, SECURE INTELLECTUAL PROPERTY, REVISIT PROMISING DRUGS OR DRUG CANDIDATES THAT HAVE BEEN SET ASIDE FOR NONMEDICAL REASONS (E.G., LACK OF EARNING POTENTIAL), AND HARNESS SCIENTIFIC AND MANUFACTURING CAPACITY IN HIGH- AND LOW- OR MIDDLE-INCOME COUNTRIES TO ENSURE DRUGS ARE AVAILABLE, ACCESSIBLE, AND AFFORDABLE TO ALL THOSE WHO NEED THEM. 0 0 2373686 2127088 ESSENTIAL MEDICINES: PDS PARTNERED WITH COLLEAGUES IN BANGLADESH TO HELP LAUNCH THE DIARRHEA INNOVATIONS GROUP, A GLOBAL NETWORK COMMITTED TO REDUCING CHILD DEATHS FROM DIARRHEAL DISEASE. THE GROUP'S PRIMARY GOAL IS TO ACCELERATE THE DEVELOPMENT AND ADOPTION OF NEW DIAGNOSTIC AND THERAPEUTIC TECHNOLOGIES WITH THE GREATEST POTENTIAL TO REDUCE CHILD DEATHS FROM DIARRHEAL DISEASE IN COUNTRIES WITH THE HIGHEST DISEASE BURDEN.TO ADDRESS CRYPTOSPORIDIUM INFECTION, ONE OF THE LEADING CAUSES OF DIARRHEAL DISEASE AMONG YOUNG CHILDREN IN LOW-RESOURCE SETTINGS, PDS WORKED WITH ACADEMIC RESEARCHERS AND OTHERS TO ADVANCE RESEARCH AND DEVELOPMENT OF DRUG CANDIDATES TO REDUCE MORTALITY AND MORBIDITY. TO COMBAT MALARIA WORLDWIDE, PDS CONTINUED WORK TO ENSURE THAT SUFFICIENT SOURCES AND QUANTITIES OF ARTEMISININ, A KEY INGREDIENT IN GOLD-STANDARD MALARIA TREATMENTS, ARE AVAILABLE TO FULLY SUPPORT CURRENT AND FUTURE USE OF ARTEMISININ-BASED COMBINATION THERAPY IN GLOBAL MALARIA CONTROL AND ELIMINATION PROGRAMS. PDS ALSO CONTINUED TO ADVANCE A LONG-ACTING INJECTABLE DRUG THAT MAY HELP PREVENT INFECTION WITH HIV WHEN USED BEFORE EXPOSURE (AN APPROACH CALLED "PRE-EXPOSURE PROPHYLAXIS, OR "PREP"). PDS PROVIDED REGULATORY SPONSORSHIP OF A PHASE 2 TRIAL TO EVALUATE THE SAFETY AND ACCEPTABILITY OF INTRAMUSCULAR INJECTIONS. BY EARLY 2016, ALL FOUR CLINICAL TRIAL SITES IN THE UNITED STATES, SOUTH AFRICA, AND ZIMBABWE HAD COMPLETED ENROLLMENT OF PARTICIPANTS, AND PDS HAD CONDUCTED SITE VISITS TO CONFIRM SITE QUALITY AND COMPLIANCE WITH THE STUDY PROTOCOL. 597372 470097 INTERNATIONAL DEVELOPMENT: IN 2016, PDS CONTINUED WORK TO REDUCE THE BURDEN OF VISCERAL LEISHMANIASIS (VL), ALSO KNOWN AS KALA-AZAR. VL IS A PARASITIC DISEASE COMMON IN AFRICA AND ASIA AND IS ALMOST ALWAYS FATAL IF UNTREATED. IN COLLABORATION WITH PARTNERS IN BANGLADESH AND NEPAL, PDS CONTINUED WORK TO STRENGTHEN NATIONAL PHARMACOVIGILANCE (PV) PROGRAMS FOR VL ELIMINATION. THE PV PROGRAMS AIM TO IMPROVE PATIENT SAFETY AND CARE ASSOCIATED WITH THE USE OF VL DRUGS, AND HAVE BEEN ACCLAIMED BY THE GOVERNMENTS OF NEPAL AND BANGLADESH. PDS ALSO ADVANCED A POST KALA-AZAR DERMAL LEISHMANIASIS (PKDL)/VL RELAPSE OBSERVATION STUDY IN BANGLADESH. PKDL SURVEILLANCE IS ESPECIALLY IMPORTANT BECAUSE THE DISEASE SERVES AS A SIGNIFICANT VECTOR FOR OVERALL VL TRANSMISSION. INTERIM DATA FOR THE MONOTHERAPY TREATMENT ARMS WERE DISSEMINATED IN 2016 WITH AN OBSERVATION OF A STRONG RELATIONSHIP BETWEEN PKDL/VL RELAPSE INCIDENCE AND THE CURRENT PRIMARY VL TREATMENT. TO BUILD CLINICAL RESEARCH CAPACITY IN INDIA, PDS WORKED TO FURTHER DEVELOP AND IMPLEMENT A CLINICAL RESEARCH TRAINING AND MENTORSHIP PROGRAM. THIS WORK WAS DONE IN COLLABORATION WITH THREE NATIONAL CLINICAL RESEARCH RESOURCE CENTERS SPECIALIZING IN PHARMACOVIGILANCE, RESEARCH ETHICS, AND DATA MANAGEMENT. 2971058 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 IN 0 0 0 0 0 0 0 0 X 8 3 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 CA WA X X OLIVIA POLIUS CHIEF FINANCIAL OFFICER 2062853500 2201 WESTLAKE AVENUE SUITE 200 SEATTLE WA 98121 STEPHEN B DAVIS PRESIDENT & CEO 1.00 39.00 X X 0 623273 62041 OLIVIA D POLIUS TREASURER & CFO 1.00 39.00 X X 0 303385 48805 DANIEL LASTER SECRETARY 1.00 39.00 X X 0 304582 42894 DAVID C KASLOW DIRECTOR 1.00 39.00 X 0 354854 63492 JORGE FLORES DIRECTOR 1.00 39.00 X 0 266659 38905 KEITH CHIRGWIN DIRECTOR 2.00 0.00 X 0 0 0 KEN DUNCAN DIRECTOR 2.00 0.00 X 0 0 0 DAN HARTMAN DIRECTOR 2.00 0.00 X 0 0 0 0 1852753 256137 0 0 1 0 0 163077 163077 50401 50401 REIMBURSEMENT 900099 3000 3000 3000 216478 0 0 53401 2358006 2358006 239179 239179 8298 8298 223925 222757 1168 2254 2254 18259 18064 195 4693 4693 107956 107956 191779 191779 17510 17510 7957 1682 6275 4452 1100 3352 SUBCONTRACTS 73591 73591 EQUIPMENT R&M 15676 15527 149 OFFSITE STORAGE 2112 527 1585 APPRECIATION GIFTS 278 278 -208 -184187 183979 3275717 2971058 304659 0 49655 48385 12733112 2045216 2048216 1933 8126443 3352 23 23869 21805 10020 2064 3736 4766 14847024 10229897 1605303 46385 1605303 46385 X 644392 490746 12597329 9692766 13241721 10183512 14847024 10229897 -3059239 1030 0 X 0 1 X 1 0 X X 1 PATH 911157127 7 1 3275717 0 1 3275717 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 23869 21805 2064 2064 1 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 21 EUROPE 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 113665 SOUTH ASIA 0 5 PROGRAM SERVICES INTERNATIONAL DEVELOPMENT 125848 SOUTH ASIA 0 0 GRANTMAKING 239179 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 647 0 5 0 0 0 5 479360 0 479360 SOUTH ASIA INTERNATIONAL DEVELOPMENT 41916 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 30083 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 154056 CHECK/WIRE SOUTH ASIA INTERNATIONAL DEVELOPMENT 8579 CHECK/WIRE 4 0 1 0 0 0 0 0 PART I, LINE 2: PDS PERFORMS RISK-BASED MONITORING OF SUBRECIPIENTS. POLICIES AND PROCEDURES ARE IN PLACE THAT GUIDE PROJECT TEAMS' FINANCIAL AND TECHNICAL MONITORING OF SUBRECIPIENTS. TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD STEWARDSHIP OF EVERY PROJECT, PDS USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, OR OTHER MEANS TO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS, AND ACHIEVES PERFORMANCE GOALS. 1 PATH 2201 WESTLAKE AVENUE SUITE 200 SEATTLE WA 98121 911157127 501(C)(3) 2358006 GENERAL SUPPORT 1 0 PART I, LINE 2: PDS PERFORMS RISK-BASED MONITORING OF SUBRECIPIENTS. POLICIES AND PROCEDURES ARE IN PLACE THAT GUIDE PROJECT TEAMS' FINANCIAL AND TECHNICAL MONITORING OF SUBRECIPIENTS. TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD STEWARDSHIP OF EVERY PROJECT, PDS USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, OR OTHER MEANS TO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS, AND THAT PERFORMANCE GOALS ARE ACHIEVED. 0 0 0 0 0 0 0 0 0 STEPHEN B DAVIS PRESIDENT & CEO 0 475514 0 143338 0 4421 0 31800 0 30241 0 685314 0 0 OLIVIA D POLIUS TREASURER & CFO 0 301435 0 0 0 1950 0 31541 0 17264 0 352190 0 0 DANIEL LASTER SECRETARY 0 302682 0 0 0 1900 0 31800 0 11094 0 347476 0 0 DAVID C KASLOW DIRECTOR 0 350433 0 0 0 4421 0 31800 0 31692 0 418346 0 0 JORGE FLORES DIRECTOR 0 266659 0 0 0 0 0 31568 0 7337 0 305564 0 0 PART I, LINE 3 PDS RELIES ON A RELATED ORGANIZATION, PATH, TO DETERMINE COMPENSATION. PATH USES THE FOLLOWING METHODS TO ESTABLISH COMPENSATION: - COMPENSATION COMMITTEE - INDEPENDENT COMPENSATION CONSULTANT - COMPENSATION SURVEY OR STUDY - APPROVAL BY THE BOARD OR COMPENSATION COMMITTEE FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM (GELMAN, ROSENBERG & FREEDMAN CPAS) USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO PATH'S BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE CHIEF FINANCIAL OFFICER SIGNED AND FILED THE RETURN. FORM 990, PART VI, SECTION B, LINE 12C PDS HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PDS BOARD MEMBERS AND OFFICERS MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. PDS DOES NOT HAVE EMPLOYEES. PDS IS A SUPPORTING ORGANIZATION TO PATH WITHIN THE MEANING OF INTERNAL REVIEW CODE SECTION 509(A)(3) AND CONTRACTS WITH PATH FOR MANAGEMENT SERVICES. PATH HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PATH BOARD MEMBERS, OFFICERS, AND STAFF AT HIGHER THAN A DESIGNATED LEVEL MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL PDS AND PATH DISCLOSURE FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. FORM 990, PART VI, SECTION C, LINE 19 PDS MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. PATH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 GLOBAL HEALTH WA 501(C)(3) LINE 7 N/A 0 PATH VACCINE SOLUTIONS 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 830431851 ADVANCE DEVELOPMENT OF VACCINES TO IMPROVE THE HEALTH OF CHILDREN WA 501(C)(3) LINE 12A, I PATH 1 FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND 207 ROUTE DE FERNEY 1218 LE GRAND-S GENEVA SZ EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH SZ 501(C)(3) PATH 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0